{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:45:06Z","timestamp":1784641506736,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10067-019-04819-4","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T10:02:38Z","timestamp":1574416958000},"page":"607-612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A critical review of the reproductive safety of Leflunomide"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2721-6624","authenticated-orcid":false,"given":"Birgit","family":"Pfaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pupco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Leibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"issue":"5","key":"4819_CR1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"C Gotestam Skorpen","year":"2016","unstructured":"Gotestam Skorpen C et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795\u2013810","journal-title":"Ann Rheum Dis"},{"key":"4819_CR2","unstructured":"Arava (leflunomide) prescribing information. Bridgewater (NJ): Sanofi-Aventis. URL: http:\/\/products.sanofi.us\/arava\/arava.html"},{"issue":"1","key":"4819_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bdra.20748","volume":"91","author":"LB Holmes","year":"2011","unstructured":"Holmes LB (2011) Human teratogens: update 2010. Birth Defects Res A Clin Mol Teratol. 91(1):1\u20137","journal-title":"Birth Defects Res A Clin Mol Teratol."},{"issue":"2","key":"4819_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/1096-9926(200102)63:2<106::AID-TERA1017>3.0.CO;2-R","volume":"63","author":"RL Brent","year":"2001","unstructured":"Brent RL (2001) Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 63(2):106\u2013112","journal-title":"Teratology"},{"issue":"3-4","key":"4819_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.reprotox.2007.05.006","volume":"24","author":"R Fukushima","year":"2007","unstructured":"Fukushima R et al (2007) Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor leflunomide in mice. Reprod Toxicol 24(3-4):310\u2013316","journal-title":"Reprod Toxicol"},{"key":"4819_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1006\/clim.1999.4777","volume":"93","author":"RI Fox","year":"1999","unstructured":"Fox RI, Herrmann ML, Frangou CG et al (1999) Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 93:198\u2013208","journal-title":"Clin Immunol"},{"issue":"2","key":"4819_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/toxsci\/kfp022","volume":"108","author":"R Fukushima","year":"2009","unstructured":"Fukushima R et al (2009) Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine. Toxicol Sci 108(2):419\u2013426","journal-title":"Toxicol Sci"},{"key":"4819_CR8","unstructured":"Aventis Pharmaceuticals Inc. Arava Tablets (leflunomide). Contraindications and warnings. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfdadocs\/label\/2003\/20905slr007,20905se1-006 arava lbl.pdf 2003 [cited31.10.16]"},{"issue":"1","key":"4819_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/ng.499","volume":"42","author":"SB Ng","year":"2010","unstructured":"Ng SB et al (2010) Exome sequencing identifies the cause of a mendelian disorder. Nat Genet 42(1):30\u201335","journal-title":"Nat Genet"},{"issue":"4","key":"4819_CR10","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1136\/annrheumdis-2017-212078","volume":"77","author":"A Berard","year":"2018","unstructured":"Berard A et al (2018) Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. Ann Rheum Dis 77(4):500\u2013509","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4819_CR11","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/art.27358","volume":"62","author":"CD Chambers","year":"2010","unstructured":"Chambers CD et al (2010) Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 62(5):1494\u20131503","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4819_CR12","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/art.34419","volume":"64","author":"M Cassina","year":"2012","unstructured":"Cassina M et al (2012) Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 64(7):2085\u20132094","journal-title":"Arthritis Rheum"},{"key":"4819_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.reprotox.2017.04.007","volume":"71","author":"C Weber-Schoendorfer","year":"2017","unstructured":"Weber-Schoendorfer C et al (2017) Leflunomide - a human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database. Reprod Toxicol 71:101\u2013107","journal-title":"Reprod Toxicol"},{"issue":"3","key":"4819_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/03009742.2011.626442","volume":"41","author":"KK Viktil","year":"2012","unstructured":"Viktil KK, Engeland A, Furu K (2012) Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol. 41(3):196\u2013201","journal-title":"Scand J Rheumatol."},{"issue":"7","key":"4819_CR15","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/ard.2004.030254","volume":"64","author":"M De Santis","year":"2005","unstructured":"De Santis M et al (2005) Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann Rheum Dis 64(7):1096\u20131097","journal-title":"Ann Rheum Dis"},{"key":"4819_CR16","first-page":"241","volume":"30","author":"EF Chakravarty","year":"2003","unstructured":"Chakravarty EF, Sanchez-Yamamoto D, Bush TM (2003) The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol. 30:241\u2013246","journal-title":"J Rheumatol."},{"key":"4819_CR17","first-page":"281","volume":"22","author":"W Paulus","year":"2006","unstructured":"Paulus W, Schloemp S, Sterzik K (2006) The use of leflunomide in fertile patients with rheumatoid arthritis [abstract]. Reprod. Toxicol. 22:281","journal-title":"Reprod. Toxicol."},{"issue":"Suppl 3","key":"4819_CR18","first-page":"A896","volume":"72","author":"O Karadag","year":"2013","unstructured":"Karadag O, Kilic L, Erbil AA et al (2013) Pregnancy outcomes of rheumatic patients with pre\/peri gestational leflunomide exposure. Ann Rheum Dis 72(Suppl 3):A896\u2013A897","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4819_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/10641950801955741","volume":"27","author":"B Kraemer","year":"2008","unstructured":"Kraemer B, Abele H, Hahn M, Rajab T, Kraemer E, Wallweiner D et al (2008) A successful pregnancy in a patient with Takayasu\u2019s arteritis. Hypertens Pregnancy. 27(3):247\u2013252","journal-title":"Hypertens Pregnancy."},{"issue":"12","key":"4819_CR20","first-page":"1069","volume":"66","author":"I Hajdyla-Banas","year":"2009","unstructured":"Hajdyla-Banas I, Banas T, Rydz-Stryszowska I, Batko B, Skura A, Gornisiewicz T et al (2009) Pregnancy course and neonatal outcome after exposure to leflunomide--2 cases report and review of literature. Przegl Lek. 66(12):1069\u20131071","journal-title":"Przegl Lek."},{"issue":"9","key":"4819_CR21","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/rheumatology\/keq132","volume":"49","author":"M Sayarlioglu","year":"2010","unstructured":"Sayarlioglu M et al (2010) Maternal exposure to leflunomide and methotrexate in a patient with adult-onset Still\u2019s disease. Rheumatology (Oxford) 49(9):1787\u20131789","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"4819_CR22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/jp.2008.118","volume":"28","author":"K Heine","year":"2008","unstructured":"Heine K, Poets CF (2008) A pair of twins born after maternal exposure to leflunomide. J Perinatol 28(12):841\u2013842","journal-title":"J Perinatol"},{"issue":"9","key":"4819_CR23","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/rheumatology\/kem170","volume":"46","author":"CE Neville","year":"2007","unstructured":"Neville CE, McNally J (2007) Maternal exposure to leflunomide associated with blindness and cerebral palsy. Rheumatology (Oxford) 46(9):1506","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"4819_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10067-008-1031-9","volume":"28","author":"Stephanie O. Keeling","year":"2008","unstructured":"Keeling, S.O. and A.E. Oswald, Pregnancy and rheumatic disease: \u201cby the book\u201d or \u201cby the doc\u201d. Clin Rheumatol, 2009. 28(1): p. 1-9.","journal-title":"Clinical Rheumatology"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04819-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04819-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04819-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T01:23:27Z","timestamp":1605921807000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04819-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["4819"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04819-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,22]]},"assertion":[{"value":"19 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S. Ito received a grant from UCB Pharma GmbH and a consultant fee from AbbVie.D. Aletaha received speaker and\/or consultancy fees from Abbvie, Amgen, Celgene, Lilly, Medac, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi\/Genzyme and grants from AbbVie, Novartis, Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}